Food and Drug Administration Commissioner Scott Gottlieb wants more drugs approved, faster. Toward that goal, the agency is permitting Sage Therapeutics (SAGE) to conduct fewer and shorter clinical trials for its second drug to treat two forms of depression, the biotech said Tuesday.

The accelerated development plan for Sage’s depression pill, called SAGE-217, emerged following a meeting with FDA regulators. If clinical trials are positive, the FDA will allow Sage to seek approval for SAGE-217 to treat major depressive disorder and postpartum depression faster than previously expected.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy